Myelofibrosis With Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment Guidelines
- 1 September 1999
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (9) , 2954
- https://doi.org/10.1200/jco.1999.17.9.2954
Abstract
PURPOSE: Myelofibrosis with myeloid metaplasia (MMM) is a chronic myeloproliferative disorder characterized by bone marrow fibrosis and extramedullary hematopoiesis. Recent studies provide definite diagnostic criteria and prognostic classifications of the disease, and allogeneic stem-cell transplantation (SCT) now offers a chance of curing the disease. In order to put diagnostic criteria and prognostic classifications of the disease into the perspective of developing guidelines for treatment strategies, all studies published in the English literature over the last 30 years were reviewed.MATERIALS AND METHODS: Studies were identified through a MEDLINE search (1966 to present) and from the bibliographies of relevant articles.RESULTS: The Italian Consensus Conference on diagnostic criteria is a structured enterprise aimed at formulating a definition of MMM that will be used for enrolling patients onto clinical studies. It relies on the obligatory presence of myelofibrosis and on the exclusion of the BCR-ABL rearrangement or Philadelphia chromosome, in association with combinations of traditional features. Prognostic scores allow us to identify classes of patients on the basis of hemoglobin, age, WBC count, and chromosomal abnormalities. Several nonrandomized studies have indicated that allogeneic SCT for patients under the age of 55 is effective in prolonging survival in more than 50% of cases and in possibly curing the disease. Patients with the most severe prognosis are candidates.CONCLUSION: “Consensus” methodology offers a definition of MMM useful for conducting and reporting clinical studies. A detailed knowledge of prognostic factors can help to delineate guidelines for addressing patients with allogeneic SCT.Keywords
This publication has 160 references indexed in Scilit:
- The role of transforming growth factor‐β in PEG‐rHuMGDF‐induced reversible myelofibrosis in ratsBritish Journal of Haematology, 1997
- Cutaneous extramedullary hematopoiesisJournal of the American Academy of Dermatology, 1995
- Raised urinary calmodulin levels in idiopathic myelofibrosis: possible implications for the aetiology of fibrosisBritish Journal of Haematology, 1994
- Plasma soluble interleukin‐2 receptor in patients with primary myelofibrosisBritish Journal of Haematology, 1994
- Serum erythropoietin in patients with myelofibrosis with myeloid metaplasiaBritish Journal of Haematology, 1993
- Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative featuresAnnals of Hematology, 1991
- Chronic Myeloproliferative Disorders in Bone Marrow BiopsiesPathology - Research and Practice, 1990
- Neutrophilic dermatosis of myeloproliferative disorders: Atypical forms of pyoderma gangrenosum and Sweet's syndrome associated with myeloproliferative disordersJournal of the American Academy of Dermatology, 1983
- The Syndrome of Idiopathic MyelofibrosisMedicine, 1983
- Zwei Fälle von Leukämie mit eigenthümlichem Blut- resp. KnochenmarksbefundVirchows Archiv, 1879